Knight Therapeutics Inc GUD-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 06/18/21 EDT
5.25quote price arrow down-0.06 (-1.13%)
Volume
147,800
52 week range
4.88 - 7.45

...

Loading . . .
  • Open5.28
  • Day High5.33
  • Day Low5.25
  • Prev Close5.31
  • 52 Week High7.45
  • 52 Week High Date06/23/20
  • 52 Week Low4.88
  • 52 Week Low Date03/04/21

Key Stats

  • Market Cap548.57M
  • Shares Out126.5M
  • 10 Day Average Volume228,873
  • Dividend-
  • Dividend Yield-
  • Beta0.64
  • YTD % Change-1.87

KEY STATS

  • Open5.28
  • Day High5.33
  • Day Low5.25
  • Prev Close5.31
  • 52 Week High7.45
  • 52 Week High Date06/23/20
  • 52 Week Low4.88
  • 52 Week Low Date03/04/21
  • Market Cap548.57M
  • Shares Out126.5M
  • 10 Day Average Volume228,873
  • Dividend-
  • Dividend Yield-
  • Beta0.64
  • YTD % Change-1.87

RATIOS/PROFITABILITY

  • EPS (TTM)0.36
  • P/E (TTM)14.51
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Knight Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

There is no recent news for this security.

Profile

MORE
Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company’s products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.
James Gale
Chairman
Jonathan Goodman
Chief Executive Officer
Samira Sakhia
President
Arvind Utchanah
Chief Financial Officer
Address
3400 De Maisonneuve Blvd W
Montreal, QC
H3Z 3B8
Canada

Top Peers

SYMBOLLASTCHG%CHG
CWEB
Direxion Daily CSI China Internet Bull 2X Shares
43.32-0.14-0.32%
HLS
NEPT
Neptune Wellness Solutions Inc
1.24-0.06-4.62%
MDP
Meredith Corp
40.31-0.72-1.75%
RX